| Vol. 11.10 – 21 March, 2023 |
| |
|
|
| Delivery of mRNA encoding a laboratory-evolved adenine base editing and guide RNA into a CD3δ severe combined immunodeficiency patient’s hematopoietic stem and progenitor cells resulted in a 71.2% ± 7.85% correction of the pathogenic mutation. [Cell] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To investigate the immunobiology of ER+ breast cancer in women with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), scientists performed phenotypic, transcriptional, and functional analyses for a cohort of treatment-naive IDC and ILC tumors. [Nature Cancer] |
|
|
|
| Researchers comprehensively profiled the genomic occupancy of mSWI/SNF chromatin remodeling complexes throughout acute and chronic T cell stimulation. [Molecular Cell] |
|
|
|
| Investigators showed the immune subset composition of the human fetal intestine during development, by longitudinal spectral flow cytometry analysis of samples between 14 and 22 weeks of gestation. [Nature Communications] |
|
|
|
| The authors reported on a heterozygous interferon regulatory factor 4 (IRF4) missense variant identified in three patients from a multigeneration family with hypogammaglobulinemia, characterizing the immunological consequences of this neomorphic mutation. [Journal Of Experimental Medicine] |
|
|
|
| Patients with stage III melanoma and high intra-tumoral interferon-γ (IFN-γ) scores were randomized to neoadjuvant nivolumab or nivolumab + domatinostat, while patients with low IFN-γ scores received nivolumab + domatinostat or ipilimumab + nivolumab + domatinostat. [Journal Of Experimental Medicine] |
|
|
|
| Scientists applied a systems approach to profile hemagglutinin- and neuraminidase-specific humoral signatures that track with the evolution of broad immunity in a cohort of vaccinated individuals and validated these findings in a second longitudinal cohort. [Cell Reports Medicine] |
|
|
|
| Researchers targeted a regulatory axis of T cell inflammatory responses, Regnase-1 and Roquin-1, to enhance antitumor responses in human T cells engineered with two clinical-stage immune receptors. [Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| In overt human B-cell malignancies, knockdown of the long plus intermediate isoforms of the PRL receptor (LF/IFPRLR) reduced B-cell viability and their MYC and BCL2 expression, and reduced the growth of human B-cell malignancies in vitro and in vivo. [Communications Biology] |
|
|
|
|
| Scientists review studies describing the connection between clonal hematopoiesis (CH) and pathological immune dysfunction, the effects of CH-associated genetic alterations on the function of myeloid and lymphoid cells, and the clinical and therapeutic implications of CH as a target for immunomodulation. [Nature Reviews Immunology] |
|
|
|
| The authors summarize our current understanding of tumor-infiltrating lymphocyte-B cells and plasma cells in human cancer, highlighting the compelling therapeutic opportunities offered by their unique tumor recognition and effector mechanisms. [Cancer Cell] |
|
|
|
|
| BioNTech and OncoC4 are partnering up to develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392, as a monotherapy or combination therapy for various cancers. [Gene Online (OncoC4)] |
|
|
|
|
| April 23 – 26, 2023 Snowbird, Utah, United States |
|
|
|
|
|
| Pfizer, Inc. – Any North American Pfizer Site |
|
|
|
| Rutgers New Jersey Medical School – Newark, New Jersey, United States |
|
|
|
| Oslo University Hospital – Oslo, Norway |
|
|
|
| Umeå University – Umeå, Sweden |
|
|
|
| University Hospital Duesseldorf – Düsseldorf, Germany |
|
|
|
|